GSK 2334470

Product Name: GSK 2334470
CAS No.: 1227911-45-6
Chemical Name: GSK 2334470
Synonyms: CS-1873;GSK 2334470;GSK 2334470 USP/EP/BP;GSK2334470 GSK-2334470;PDK1 inhibitor GS2334470;GSK2334470;GSK 2334470;GSK-2334470;1S,4R)-3-(6-(3-AMINO-1H-INDAZOL-6-YL)-2-(METHYLAMINO)PYRIMIDIN-4-YL)-N-CYCLOHEXYL-4-METHYLCYCLOHEXAN;1S,4R)-3-(6-(3-aMino-1H-indazol-6-yl)-2-(MethylaMino)pyriMidin-4-yl)-N-cyclohexyl-4-MethylcyclohexanecarboxaMide;(3S,6R)-1-[6-(3-Amino-1H-indazol-6-yl)-2-(methylamino)-4-pyrimidinyl]-N-cyclohexyl-6-methyl-3-piperidinecarboxamide;((3S,6R)-1-(6-(3-amino-1H-indazol-6-yl)-2-(methylamino)pyrimidin-4-yl)-6-methylpiperidin-3-yl)(piperidin-1-yl)methanone
CBNumber: CB62596521
Molecular Formula: C25H34N8O
Formula Weight: 462.59
MOL File: 1227911-45-6.mol

More

Less

GSK 2334470 Property

Density: 1.30±0.1 g/cm3(Predicted)
storage temp.: 2-8°C
solubility: DMSO: ≥10mg/mL
pka: 12.84±0.40(Predicted)
form: powder
color: white to light brown
Stability:: Stable for 1 year as supplied. Solutions in DMSO may be stored at -20° for up to 3 months.

More

Less

Safety

WGK Germany: 3

More

Less

Hazard and Precautionary Statements (GHS)

More

Less

N-Bromosuccinimide Price

Sigma-Aldrich

Product number: SML0217
Product name: GSK2334470
Purity: ≥98% (HPLC)
Packaging: 5mg
Price: $161
Updated: 2024/03/01

Sigma-Aldrich

Product number: SML0217
Product name: GSK2334470
Purity: ≥98% (HPLC)
Packaging: 25mg
Price: $517
Updated: 2024/03/01

Cayman Chemical

Product number: 18095
Product name: GSK2334470
Purity: ≥98%
Packaging: 5mg
Price: $76
Updated: 2024/03/01

Cayman Chemical

Product number: 18095
Product name: GSK2334470
Purity: ≥98%
Packaging: 10mg
Price: $142
Updated: 2024/03/01

Cayman Chemical

Product number: 18095
Product name: GSK2334470
Purity: ≥98%
Packaging: 25mg
Price: $335
Updated: 2024/03/01

More

Less

GSK 2334470 Chemical Properties,Usage,Production

Description

GSK2334470 (1227911-45-6)?is a potent (IC50?= 10 nM) and selective inhibitor of 3-Phosphoinositide-dependent kinase 1 (PDK1), which phosphorylates and activates a group of protein kinases in the AGC/PKG/PKC family.1?It is more effective at inhibiting PDK1 substrates that are activated in the cytosol rather than at the plasma membrane.1?GSK2334470 delayed melanogenesis and metastasis in Braf(V600E)::Pten(-/-)?mice.2?It also displays antitumor activity against multiple myeloma synergistically with mTORC1/2 inhibitor PP2423?and proteasome inhibitor MG-1324.

Uses

GSK2334470 has been used as an inhibitor of 3-phosphoinositide dependent protein kinase-1 (PDK-1) in:

Treg cells, to identify regulators of interleukin 2 (IL-2)– signal transducer and activator of transcription 5 (STAT5) signaling
glycodelin-transfected HEC-1B human endometrial adenocarcinoma cells.
HeLa and Hs578T cells to test its effect on formylglycinamidine ribonucleotide synthase?(FGAMS) assembly

Definition

ChEBI: (3S,6R)-1-[6-(3-amino-1H-indazol-6-yl)-2-(methylamino)-4-pyrimidinyl]-N-cyclohexyl-6-methyl-3-piperidinecarboxamide is a member of indazoles.

Biochem/physiol Actions

GSK2334470 (GSK-470) mediates cell cycle arrest. It also inhibits cellular proliferation and induces apoptosis in cancer cells.

storage

Store at +4°C

References

1) Najafov?et al.?(2011), Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1; Biochem.J.?433?37 2) Scortegagna?et al.?(2014), Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf (V600E)::Pten(-/-) melanoma; Oncogene?33?4330 3) Yang?et al.?(2017),PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242; Oncotarget?8?39185 4) Zhang?et al.?(2018), PDK1 inhibitor GSK2334470 synergizes with proteasome inhibitor MG-132 in multiple myeloma cells by inhibiting full AKT activity and increasing nuclear accumulation of PTEN protein; Oncol.Rep.?39 2951

GSK 2334470 Preparation Products And Raw materials

Raw materials

Preparation Products

More

Less

GSK 2334470 Suppliers

China 85 India 1 United Kingdom 1 United States 20 Global 107

Chengdu Lanqingting Biotech Company Limited

Tel: 028-87856149; 15208320722
Email: 1813129729@qq.com
Country: China
ProdList: 288
Advantage: 58

Shanghai Boyle Chemical Co., Ltd.

Tel
Fax: 86-21-57758967
Email: sales@boylechem.com
Country: China
ProdList: 2922
Advantage: 55

Chembest Research Laboratories Limited

Tel: +86-21-20908456
Fax: 021-58180499
Email: sales@BioChemBest.com
Country: China
ProdList: 6005
Advantage: 61

Jinan Trio PharmaTech Co., Ltd.

Tel: +86 (531) 88811783
Fax: +86 (531) 55696010 QQ 1762738062
Email: sales@trio-pharmatech.com (International market)
Country: China
ProdList: 1856
Advantage: 62

Dalian Meilun Biotech Co., Ltd.

Tel: 0411-62910999 13889544652
Email: meilunui@163.com
Country: China
ProdList: 4727
Advantage: 58

Jiangsu Aikon Biopharmaceutical R&D co.,Ltd.

Tel: 025-66099280 17798518460
Fax: (1)02557626880
Email: cfzhang@aikonchem.com
Country: China
ProdList: 19915
Advantage: 55

Haoyuan Chemexpress Co., Ltd.

Tel: 021-58950125
Fax: (86) 21-58955996
Email: info@chemexpress.com
Country: China
ProdList: 7552
Advantage: 61

Shanghai Aladdin Bio-Chem Technology Co.,LTD

Tel: 400-400-6206333 18521732826
Fax: 021-50323701
Email: market@aladdin-e.com
Country: China
ProdList: 25003
Advantage: 65

MedChemexpress LLC

Tel: 021-58955995
Fax: 609-228-5909
Email: sales@medchemexpress.cn
Country: United States
ProdList: 4861
Advantage: 58

AdooQ BioScience, LLC

Tel: +1 (866) 930-6790
Fax: +1 (866) 333-9607
Email: info@adooq.com
Country: United States
ProdList: 2782
Advantage: 58

1227911-45-6, GSK 2334470Related Search:

S)-1-(sec-butyl)-N-((4,6-diMethyl-2-oxo-1,2-dihydropyridin-3-yl)Methyl)-3-Methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxaMide GSK864 GSK484 GSK J4 HCl GSK2982772 GSK2636771 Benzeneacetamide, α-[[6-(4-amino-1-piperidinyl)-3,5-dicyano-4-ethyl-2-pyridinyl]thio]- GSK778 N-(6-Fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide Sunitinib Malate 17-AAG Brefeldin A SU 4312 Bortezomib Y27632 (hydrochloride) MK-1775 Axitinib Pictilisib

GSK 2334470

1S,4R)-3-(6-(3-aMino-1H-indazol-6-yl)-2-(MethylaMino)pyriMidin-4-yl)-N-cyclohexyl-4-MethylcyclohexanecarboxaMide

(3S,6R)-1-[6-(3-Amino-1H-indazol-6-yl)-2-(methylamino)-4-pyrimidinyl]-N-cyclohexyl-6-methyl-3-piperidinecarboxamide

3-Piperidinecarboxamide, 1-[6-(3-amino-1H-indazol-6-yl)-2-(methylamino)-4-pyrimidinyl]-N-cyclohexyl-6-methyl-, (3S,6R)-

(3S,6R)-1-[6-(3-Amino-1H-indazol-6-yl)-2-(methylamino)-4-pyrimidinyl]-N-cyclohexyl-6-methyl-3-piperidinecarboxamide GSK 2334470

GSK2334470;GSK 2334470;GSK-2334470

((3S,6R)-1-(6-(3-amino-1H-indazol-6-yl)-2-(methylamino)pyrimidin-4-yl)-6-methylpiperidin-3-yl)(piperidin-1-yl)methanone

1S,4R)-3-(6-(3-AMINO-1H-INDAZOL-6-YL)-2-(METHYLAMINO)PYRIMIDIN-4-YL)-N-CYCLOHEXYL-4-METHYLCYCLOHEXAN

PDK1 inhibitor GS2334470

CS-1873

GSK 2334470 USP/EP/BP

GSK2334470 GSK-2334470

1227911-45-6

C25H34N8O

Inhibitors

Akt

mTOR

PI3K

PI3K/Akt/mTOR

API